Therapeutic effect of metoprolol combined trimetazidine on ischemic heart failure and its influence on inflammatory factors
10.3969/j.issn.1008-0074.2018.01.12
- VernacularTitle:美托洛尔联合曲美他嗪治疗缺血性心力衰竭及其对炎性因子的影响
- Author:
Hai-Yan LI
1
;
Yong-Chun WANG
;
Hui NIU
;
Chun-Ling ZHAO
;
Li-Juan XIE
;
Guo-Hua WANG
Author Information
1. 河北省三河市燕郊人民医院心肾内科
- Keywords:
Heart failure;
Metoprolol;
Trimetazidine
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2018;27(1):42-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study therapeutic effect of metoprolol combined trimetazidine on ischemic heart failure (IHF) and its influence on inflammatory factors. Methods: A total of 172 IHF patients treated in our hospital were collected. They were randomly and equally divided into trimetazidine group and combined treatment group (received metoprolol combined trimetazidine), and both groups were treated for 30d. Cardiac function, levels of inflammatory factors, N terminal pro brain natriuretic peptide (NT-proBNP), heart type fatty acid-binding protein (H-FABP) and quality of life (QOL) before and after treatment, and cerebral infarction rate after one-year treatment were compared between two groups. Results: Compared with trimetazidine group after treatment, there were significant rise in left ventricular ejection fraction [(44. 68±4. 51) ％ vs. (49. 79±4. 99) ％], significant reductions in left ventricular end-diastolic dimension [(50. 41± 5. 06) mm vs. (47. 28±4. 83) mm], left ventricular end-systolic dimension [(41. 57±4. 22) mm vs. (36. 72±3. 71) mm], levels of NT-proBNP [(3. 48±0. 35) ng/L vs. (3. 06±0. 32) ng/L], H-FABP [(11. 41±1. 26) μg/L vs. (8. 55±0. 86) μg/L], interleukin 6 [(53. 21±5. 36) ng/L vs. (43. 58±4. 44) ng/L], tumor necrosis factorα [(161. 97±16. 28) ng/L vs. (108. 27±10. 11) ng/L]and C reactive protein [(15. 72±1. 59) ng/L vs. (11. 10±1. 12) ng/L]and QOL score [(48. 75±4. 89) scores vs. (43. 15±4. 33) scores]in combined treatment group, P＜0. 05 or＜0. 01. Total effective rate of combined treatment group was significantly higher than that of trimetazidine group (90. 70％ vs. 72. 09％, P=0. 002); after one-year treatment, incidence rate of cerebral infarction in combined treatment group was significantly lower than that of trimetazidine group (2. 33％ vs. 10. 47％, P=0. 029). Conclusion: Metoprolol combined trimetazidine can significantly improve myocardial blood supply, correct immune imbalance, improve cardiac function and quality of life in IHF patients. The therapeutic effect is significant, and it can prevent cerebral infraction, which is worth extending.
